Location San Francisco, California, United States Regions San Francisco Bay Area, West Coast, Western US Gender Male
LinkedIn View on LinkedIn
A scientist and business professional, Euan Thomson’s commitment to innovation has enabled him to play pioneering roles with a series of breakthrough technologies. Prior to joining Khosla Ventures, Euan had more than 14 years of experience as a CEO, managing both private and public companies.
Trained as a physicist at the University of London,
Euan devoted more than fifteen years to research, teaching, clinical practice, and administration within the United Kingdom health care system. In parallel, Euan formed a successful consultancy practice, providing advice for companies and hospitals on scientific development, product marketing, and management. Serving premier clients such as Varian Medical Systems and Radionics, Inc., he cultivated a specialty in development, positioning, regulatory approvals, pricing, and reimbursement of U.S. products for international markets.
In 2002, Euan joined Accuray Inc., then a small, privately-held company. Directing the company’s evolution from its latent promise to a global company, he applied his foundation of science and technological expertise to secure worldwide clinical acceptance for CyberKnife® Radiosurgery through the creation of protocols and studies for treatment of tumors in the brain, spine, lung, liver, pancreas, prostate and breast; and improved Accuray’s intellectual property portfolio from five issued U.S. patents in FY 2001 to 290 issued U.S. and Foreign patents by the end of 2012. Expanding both the reach and scope of the organization, Euan built distribution channels in more than 80 countries; he executed a strategic sales alliance with Siemens Healthcare and consummated the successful acquisition of TomoTherapy®, Inc. in 2011. Both at Accuray and his prior company, Photoelectron Inc, Euan initiated and directed a host of sophisticated financial transactions including private and public investments and Initial Public Offerings. The successful 2007 Accuray IPO was priced above range, and approximately 10x oversubscribed. Applying considerable business acumen to his role at Accuray, he has oversaw exponential revenue growth from $10 million in 2002 to more than $400 million in fiscal year 2012.
Euan is a member of the Board of Directors of the Hospice of the Valley, a hospice facility serving individuals with life-limiting illnesses. Euan has served as Chair of the California Division of the American Cancer Society’s CEO’s Against Cancer. He is the recipient of an Ernst and Young Entrepreneur of the Year award (N. California, Health & Life Sciences), and an ABBY Award from the Adaptive Business Leaders Organization for his innovation in biotechnology. Having earned a B.S. in Physics, an M.S. in Radiation Physics, and a Ph.D. in Physics, Euan is the author of numerous scientific papers and personally holds six U.S. patents.
